As a CAR technology leader, Creative Biolabs has established an unparalleled platform for Chimeric Antigen Receptor (CAR) modified T cell construction, which can satisfy various needs for developing treatments of multiply cancers in preclinical studies and researches.
From Racing CARs against Cancer. Posted on April 15, 2013. Science in the News website.
In addition to CAR construction, Creative Biolabs can also construct various CAR-T cells, which has been used in the promising adoptive CAR-T cell therapy for treating various cancers. Our elite scientists have broad experience in CAR technology. Firstly, we generate CAR construction including a single-chain variable fragment (scFv), a hinge or spacer region, a transmembrane domain (TM) and an endodomain (or two). After packaging the vector, we will produce transduction-ready pseudoviral particles with high titers and transduce these highly effective pseudoviral particles into T cells. Once binding the specific antigens, the endodomain of CAR such as CD3ζ intracellular signaling domain or Fc receptor γ cytoplasmic signaling domains (FcεRIγ) can subsequently activate T cells which can directly kill cancer cells.
Alternatively, Creative Biolabs can also provide bispecific CAR technology service according to your specific requirements. The bispecific CAR has another binding domain which can regulate the CAR activation and enhance the specificity of our CAR-T cells products.
Copyright © 2007 - 2019 Creative Biolabs. All Rights Reserved